Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus Infection Genotypes 1 and 3
Novelty in Biomedicine,
Vol. 8 No. 4 (2020),
29 November 2020
,
Page 171-181
https://doi.org/10.22037/nbm.v1i1.29735
Abstract
Background: The new direct-acting antiviral agents (DAAs) with high efficacy, low resistance, and low rate of adverse events (AEs) have shown promising outcomes for hepatitis C virus (HCV) treatment. This study assessed the efficacy and safety of Daclatasvir/Sofosbuvir (DCV/SOF) compared to Ledipasvir/Sofosbuvir (LDV/SOF) in patients with HCV infection in the real-world setting in Iran.Materials and Methods: A total of 42 patients with HCV infection were treated with either LDV/SOF (genotype 1) or DCV/SOF (genotypes 1, 3 or unknown) with or without ribavirin (RBV). Assessment of risk factors, laboratory tests, sustained virologic response at post-treatment week 12 (SVR12), and AEs were performed.
Results: The highest risk factor for HCV transmission was major surgery (50.0%), followed by tattooing (40.5%), phlebotomy (40.5%), and dental surgery (40.5%). No statistically significant relationships between genotypes and risk factors were observed. In both treatment groups (LDV/SOF and DCV/SOF), all of the patients (100%) with or without cirrhosis and treatment-experience achieved SVR12. One patient with a history of failed LDV/SOF therapy achieved SVR12 following retreatment with DCV/SOF. Both treatment regimens were well-tolerated. No serious AEs or discontinuation due to AEs was observed. The most common AE across both treatment groups were fatigue (42.9%), followed by anxiety (28.6%). Numerically, more adverse events were found with the LDV/SOF regimen than with the DCV/SOF regimen.
Conclusion: Our study showed an excellent safety and efficacy of DCV/SOF and LDV/SOF in Iranian patients infected with HCV. The incidence of AEs among patients treated with LDV/SOF was higher than those receiving SOF/DCV.
- Hepatitis C, Real-world data, Direct-acting antiviral agents, Risk factors
How to Cite
References
Sorbo MC, Cento V, Di Maio VC, Howe AY, Garcia F, Perno CF, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. 2018; 37:17-39.
Alavian SM, Hajarizadeh B, Lankarani KB, Sharafi H, Daryani NE, Merat S, et al. Recommendations for the clinical management of hepatitis C in Iran: a consensus-based national guideline. 2016;16(8).
Chayama K, Imamura M, Hayes CNJAiDM. Hepatitis C virus treatment update—a new era of all-oral HCV treatment. 2016;3(4):153-60.
Friedrich-Rust M, Zeuzem S, Sarrazin CJIjocd. Current therapy for hepatitis C. 2007;22(4):341-349.
Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi HJAoh. Combination of Ledipasvir and Sofosbuvir for treatment of hepatitis C virus genotype 1 infection: systematic review and meta-analysis. 2017; 16(2):188-197.
Sefidi FJ, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim FJHm. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. 2013; 13(1).
Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti CJWjog. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. 2016;22(34):7824.
Nguyen MH, Trinh H, Do S, Nguyen T, Nguyen P, Henry LJTAjog. Open label study of 8 vs. 12 weeks of ledipasvir/sofosbuvir in genotype 6 treatment naive or experienced patients. 2017;112(12):1824.
Alavian SM, Rezaee-Zavareh MSJHm. Daclatasvir-based treatment regimens for hepatitis C virus infection: a systematic review and meta-analysis. 2016;16(9).
Kermani FR, Amini-Kafiabad S, Hosseini KM, Maghsudlu M, Sharifi Z, Mansournia MAJJJoM. Distribution of Hepatitis C Virus Genotypes and Related Risk Factors Among Iranian Blood Donors: A Penalized Logistic Regression. 2018;In Press.
Sofian M, Ramezani A, Imani H, Farazi AA, Banifazl M, Jourabchi A, et al. Distribution of hepatitis C virus genotypes in Arak city, central province of Iran. 2016;8(5):321.
Ansari N, Doosti M, Ahmadi A, Kakavandi E, Yazdani S, Shayestehpour MJIJoV. Distribution of Hepatitis C virus genotypes in Yazd, Central Province of Iran: increasing the mixed genotypes. 2016;10(2):19-24.
Janiak M, Caraballo Cortés K, Perlejewski K, Kubicka-Russel D, Grabarczyk P, Demkow U, et al. Next-Generation Sequencing of Hepatitis C Virus (HCV) Mixed-Genotype Infections in Anti-HCV-Negative Blood Donors. 2018:65-71.
Rafiei A, Darzyani AM, Taheri S, Haghshenas M, Hosseinian A, Makhlough AJAPjotm. Genetic diversity of HCV among various high risk populations (IDAs, thalassemia, hemophilia, HD patients) in Iran. 2013;6(7):556-60.
Alavian S, FALAHIAN F. Epidemiology of Hepatitis C in Iran and the World; 2009.
Mahmud S, Akbarzadeh V, Abu-Raddad LJJSr. The epidemiology of hepatitis C virus in Iran: systematic review and meta-analyses. 2018;8(1):150.
Miri SM, Alavian SMJJJoM. Increasing the HCV Prevalence in Ahvaz: Bells Ring!! 2013;6(3):309.
Savvas S, Koskinas J, Sinani C, Hadziyannis A, Spanou F, Hadziyannis SJJovh. Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. 2005;12(5):551-7.
Elghouzzi M, Bouchardeau F, Pillonel J, Boiret E, Tirtaine C, Barlet V, et al. Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors. 2000;79(3):138-44.
Hussain A, Idrees MJVj. The first complete genome sequence of HCV-1a from Pakistan and a phylogenetic analysis with complete genomes from the rest of the world. 2013;10(1):211.
Daw MA, El-Bouzedi A, Dau AAJBrn. Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission. 2015;8(1):367.
Škamperle M, Seme K, Lunar MM, Maver PJ, Tomažič J, Vovko TD, et al. Prevalence, genotype distribution, and risk factors for hepatitis C infection among HIV-infected individuals in Slovenia: a 1986-2013 update. 2014;23(2):25-6.
Bourliere M, Barberin J, Rotily M, Guagliardo V, Portal I, Lecomte L, et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. 2002;9(1):62-70.
Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. 2015;62(1):25-30.
Kouris G, Hydery T, Greenwood BC, Lavitas P, Price M, Clements K, et al. Effectiveness of Ledipasvir/Sofosbuvir and predictors of treatment failure in members with hepatitis C genotype 1 infection: A retrospective cohort study in a medicaid population. 2018; 24(7):591-7.
Mehta V, Mahajan R, Midha V, Narang V, Kaur K, Singh A, et al. Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India. 2018;8(1):7-14.
Liu C-H, Liu C-J, Su T-H, Yang H-C, Hong C-M, Tseng T-C, et al. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. 2018;13(12):e0209299.
Gayam V, Tiongson B, Khalid M, Mandal AK, Mukhtar O, Gill A, et al. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African–American patients: a community-based retrospective cohort study. 2018;30(10):1200.
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study. 2015;61(4):1127-35.
Hézode C, Lebray P, De Ledinghen V, Zoulim F, Di Martino V, Boyer N, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. 2017;37(9):1314-24.
Pol S, Corouge M, Vallet-Pichard AJHme, research. Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. 2016;8:21.
Hong C-M, Liu C-H, Su T-H, Yang H-C, Chen P-J, Chen Y-W, et al. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. 2018.
Pol S, Bourlière M, Lucier S, Hézode C, Dorival C, Larrey D, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. 2017;66(1):39-47.
- Abstract Viewed: 304 times
- PDF Downloaded: 108 times